BAY 1161909

Drug Profile

BAY 1161909

Alternative Names: BAY-1161909

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 14 Apr 2016 Phase-I development is ongoing in USA
  • 08 May 2014 Preclinical trials in Solid tumours in Germany (PO)
  • 08 May 2014 Bayer plans a phase I trial for Solid tumours (combination therapy, late-stage disease, second-line therapy or greater) in USA (NCT02138812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top